ASCO/EHA/ICML 2023 – Philipp Staber
Philipp Staber explains the role of functional drug testing in the treatment of patients with hematologic diseases, shares the rationale of the EXALT-2 trial as well as his thoughts on future developments in the field of precision medicine. Finally, he gives insights in the current research topics of the EHA SWG-Precision Hematology and their goal for the next five years.
Here is the full ASCO/EHA/ICML 2023 report.
More posts
DLBCL: treatment of elderly patients and relapsed disease
DLBCL: treatment of elderly patients and relapsed disease POLAR BEAR: novel regimen fr
Waldenström macroglobulinemia: findings from ASPEN and BRUIN
Waldenström macroglobulinemia: findings from ASPEN and BRUIN ASPEN: HRQoL for zanubrut
Outcome improvements in relapsed and untreated marginal zone lymphoma
Outcome improvements in relapsed and untreated marginal zone lymphoma Final analysis o
Follicular lymphoma: study results with bispecific antibodies and BTK inhibitors
Follicular lymphoma: study results with bispecific antibodies and BTK inhibitors Mosun
Current insights into BTK inhibition and other targeted approaches in CLL
Current insights into BTK inhibition and other targeted approaches in CLL Treatment-na
Preface – ASCO/EHA/ICML 2023
Preface – ASCO/EHA/ICML 2023 © Dirk Gillissen – Arnon P. Kater, MD, PhD, Department o
